NCT03823378
Brief summary
This is a long-term extension (LTE) study to assess the safety, tolerability and efficacy of an active drug and an active drug in Rheumatoid Arthritis (RA) participants who have completed M16-063
Interventional study
- 1
- 2
- 3
- 4
Would you like to know more about this trial?
Please note, participation in the clinical trial is open to patients with the disease or condition under investigation. |
Age:
18 Years and older.
Inclusion Criteria: - Participant has completed Study M16-063 - Participant has not developed any laboratory or clinical discontinuation criteria as defined in the Study M16-063 protocol - Participant is willing and/or able to comply with procedures required in the current study protocol Exclusion Criteria: - Participant is currently enrolled or planning to enroll in another interventional clinical study while participating in this study (except the preceding study M16-063) - Participant requires vaccination with any live vaccine during study participation, including at least 30 days after the last dose of study drug